The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - A second late-stage study of Incyte’s (INCY) Jakafi (ruxolitinib) in polycythemia vera (PV) failed on Wednesday, though the company says the study isn’t necessary for FDA approval. RELIEF was … Continue Reading
Read nowInsights - Biogen Idec (BIIB) trounced analyst estimates on Wednesday, a beat led by $700 million in Tecfidera sales during the quarter that topped consensus estimates for $561 million. Ex-U.S., the … Continue Reading
Read nowInsights - Puma Biotechnology (PUMA) shares ripped higher by 200% in after-hours trading on Tuesday with positive results from a late-stage trial of Puma’s experimental breast cancer drug, neratinib. The ExteNET … Continue Reading
Read nowInsights - With Sandoz deal, Anacor (ANAC) investors can get a little more comfortable with the upcoming commercial launch.
Read nowRecap - In the three trading sessions following the Fed’s semi-annual monetary policy report, in which the fed specifically called out small biotech equities as overvalued, the iShares … Continue Reading
Read nowResearch - Investors are skittish again, and healthcare investors more than others. Here’s why. In the Fed’s semi-annual monetary policy report, which accompanied Chairwoman Janet Yellen’s testimony before … Continue Reading
PremiumInsights - Prana Biotech (PRAN) said on Thursday that after further analysis of a failed Alzheimer’s study, the company will likely move forward with lead drug candidate PBT2 in … Continue Reading
Read now
